Liz-M Tablet SR is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, formulated for sustained release to provide effective glycemic control in patients with type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels, while Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. The sustained-release formulation ensures a gradual release of active ingredients, enhancing patient compliance by reducing dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release Metformin. Liz-M Tablet SR is indicated as an adjunct to diet and exercise for the management of type 2 diabetes when monotherapy with either agent is inadequate. It is essential to monitor blood glucose levels regularly to avoid hypoglycemia, especially in patients with renal or hepatic impairment. Contraindications include severe renal dysfunction, metabolic acidosis, and hypersensitivity to either component. Caution is advised in patients with cardiovascular disease or during periods of acute illness. This combination therapy offers a complementary mechanism of action, improving glycemic control and reducing the risk of diabetes-related complications when used appropriately under medical supervision.